U.S. stocks are drifting near their record heights as Wall Street waits for an upcoming update on inflation.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1 ...

Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...

Gilead Sciences has secured approval from the United States health authorities for its new HIV prevention injection, Yeztugo, but concerns are growing over its steep price tag.

Wall Street and the Fed will get more insight next week on inflation’s temperature and the economy. The government will ...

Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc.

On August 11, Sensex closed 746.29 points or 0.93 percent higher at 80,604.08, and the Nifty ended 221.75 points or 0.91 ...

Gift Nifty was trading 24,447 around level, a premium of nearly 6 points from the Nifty futures’ previous close, indicating a ...

The global regenerative medicine market, valued at US$13.5 billion in 2022, stood at US$16.0 billion in 2023 and is projected to advance at a resilient CAGR of 25.1% from 2023 to 2028, culminating in ...

Assembly Biosciences ( ($ASMB) ) just unveiled an announcement. On August 8, 2025, Assembly Biosciences announced the pricing of a $175 million ...